Skip to Main Content
Table 1.
Demographic and clinical characteristics, and hematological and clinical biochemistry findings of COVID-19 patients
Patient no.1234
Gender 
Age (yr) 56 63 51 73 
Known comorbidities Emphysema, extrinsic asthma Type 2 diabetes, obesity, hyperanxiety, epilepsy Type 2 diabetes, hypertension, fatty liver None 
Chronic treatments Inhaled CS and β2 agonists, leukotriene receptor antagonists, SSRI Anti-diabetes (metformin), neuroleptic (haloperidol), anxiolytic (prothipendyl), anti-epileptic (sodium valproate), L-thyroxin, anti-convulsive (procyclidin) Anti-diabetes (metformin, empagliflozine), anti-hypertensive (ACE inhibitor, angiotensin 2 receptor antagonist), α1 receptor antagonists L-thyroxin, aspirin 
Time from admission to death (d) 18 32 22 
Symptom duration before admission (d) 
Duration of ventilator management (d) 15 32 22 
Secondary lung infection No No Yes Yes 
Secondary disorder Renal failure Pneumothorax Renal failure, hypercortisolemia Renal failure, atrial fibrillation 
In-hospital antiviral therapy (hydroxychloroquine) Yes Yes Yes Yes 
In-hospital antibiotic therapy Yes Yes Yes Yes 
In-hospital antifungal therapy No No Yes No 
In-hospital anticoagulant therapy (heparin) Yes No No No 
Cause of death ARDS, multi-organ failure Pneumonia ARDS ARDS 
Diffuse alveolar damage Yes Yes Yes Yes 
Lymphocytes [1.1–4.5 103/μl] 1.41 0.17a 0.97a Below detectiona 
Neutrophils [1.5–4.5 103/μl] 25.84b 8.7b 6.93b 18.35b 
Monocytes [0.1–0.9 103/μl] 1.61b 0.34 0.75 Below detectiona 
Platelets [150–370 103/µl] 7a 217 70a 26a 
CRP [0–5 µg/ml] 391.4b 286.8b 183.3b 231b 
Fibrinogen [1.79–3.86 mg/ml] 4.43b 7.55b 3.47 5.70b 
IL-6 [< 1 IU/ml] Not measured 384.8b 129.3b 1,077.3b 
D-dimer [< 500 µg/liter] 2,106b 7,440b 9,149b 4,559b 
Patient no.1234
Gender 
Age (yr) 56 63 51 73 
Known comorbidities Emphysema, extrinsic asthma Type 2 diabetes, obesity, hyperanxiety, epilepsy Type 2 diabetes, hypertension, fatty liver None 
Chronic treatments Inhaled CS and β2 agonists, leukotriene receptor antagonists, SSRI Anti-diabetes (metformin), neuroleptic (haloperidol), anxiolytic (prothipendyl), anti-epileptic (sodium valproate), L-thyroxin, anti-convulsive (procyclidin) Anti-diabetes (metformin, empagliflozine), anti-hypertensive (ACE inhibitor, angiotensin 2 receptor antagonist), α1 receptor antagonists L-thyroxin, aspirin 
Time from admission to death (d) 18 32 22 
Symptom duration before admission (d) 
Duration of ventilator management (d) 15 32 22 
Secondary lung infection No No Yes Yes 
Secondary disorder Renal failure Pneumothorax Renal failure, hypercortisolemia Renal failure, atrial fibrillation 
In-hospital antiviral therapy (hydroxychloroquine) Yes Yes Yes Yes 
In-hospital antibiotic therapy Yes Yes Yes Yes 
In-hospital antifungal therapy No No Yes No 
In-hospital anticoagulant therapy (heparin) Yes No No No 
Cause of death ARDS, multi-organ failure Pneumonia ARDS ARDS 
Diffuse alveolar damage Yes Yes Yes Yes 
Lymphocytes [1.1–4.5 103/μl] 1.41 0.17a 0.97a Below detectiona 
Neutrophils [1.5–4.5 103/μl] 25.84b 8.7b 6.93b 18.35b 
Monocytes [0.1–0.9 103/μl] 1.61b 0.34 0.75 Below detectiona 
Platelets [150–370 103/µl] 7a 217 70a 26a 
CRP [0–5 µg/ml] 391.4b 286.8b 183.3b 231b 
Fibrinogen [1.79–3.86 mg/ml] 4.43b 7.55b 3.47 5.70b 
IL-6 [< 1 IU/ml] Not measured 384.8b 129.3b 1,077.3b 
D-dimer [< 500 µg/liter] 2,106b 7,440b 9,149b 4,559b 

For hematological and clinical biochemistry values, references ranges are indicated in brackets. ACE, angiotensin-converting enzyme; CRP, C-reactive protein; CS, corticosteroids; F, female; M, male; SSRI, selective serotonin reuptake inhibitor.

a

Values below the reference range.

b

Values above the reference range.

Close Modal

or Create an Account

Close Modal
Close Modal